Clinical Trials
5 trialsNCT02962414 2026-04-02
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT07403266 2026-02-11
Spectrum
Oils4Cure
Phase 3 Recruiting
NCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT05604170 2025-10-01
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Terminated
NCT05323734 2025-07-11
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Completed